Blocking CCL9 inhibited Hepa1-6 tumor growth, further demonstrating that CCL9 is a key downstream molecule of MyD88 in myofibroblasts in obesity-related liver cancer (Fig. 7). The gene discussed is MYD88; the disease is obesity due to melanocortin 4 receptor deficiency.